# Casodex vs Placebo in Non-Metastatic Early Prostate Cancer

> **NCT00672282** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 1218 (actual)

## Conditions studied

- Non-Metastatic Prostate Cancer

## Interventions

- **DRUG:** Bicalutamide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00672282
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1995-10
- **Primary completion:** —
- **Final completion:** 2008-08
- **Target enrollment:** 1218 (ACTUAL)
- **Last updated:** 2009-05-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00672282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00672282, "Casodex vs Placebo in Non-Metastatic Early Prostate Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00672282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*